069620 — Daewoong Pharma Share News
0.000.00%
Last trade - 00:00- KR₩1tn
- KR₩2tn
- KR₩2tn
Brief: Daewoong Pharma Wins 92.6 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 45.5 Billion Won, Up 9% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 62.5 Billion Won, Up 26% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 42 Billion Won, Up 34.5% From Year Earlier
Brief: Daewoong Pharma Wins 180.5 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 42 Billion Won, Up 30.4% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 49.6 Billion Won, Up 37% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 31.2 Billion Won, Up 0.8% From Year Earlier
Brief: Daewoong Pharma To Pay Dividend Of 600 Won Per Common Share
Brief: Daewoong Pharma Q4 Operating Profit 32 Billion Won, Up 109.4% From Year Earlier
Brief: CGBio's 'Novosis Putty' Receives FDA 'Breakthrough Device Designation'
Brief: Daewoong Pharma Wins 122 Billion Won Order
Brief: Daewoong Pharma Wins 77 Billion Won Order
Brief: Daewoong Pharma Q3 Operating Profit 34 Billion Won, Up 13% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 36.2 Billion Won, Up 7.8% From Year Earlier
Brief: Daewoong Pharmaceutical Regaining Rights To Fexuprazan In The United States And Canada Upon Termination Of License Agreement With Neurogastrx
Development Agreement With Nurron Pharmaceuticals To Develop Therapy For Parkinson's Disease
Brief: Daewoong Pharma - Submitted An NDA To Indonesia, Philippines And Thailand For Envlo
Brief: Daewoong Pharma Wins 110 Billion Won Order